Skip to content

18F-DOPA PET/CT in the diagnosis of Parkinson's disease: a cross-sectional, associated clinical study

18F-DOPA PET/CT in the diagnosis of Parkinson's disease: a cross-sectional, associated clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095420
Enrollment
Unknown
Registered
2025-01-07
Start date
2025-01-07
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Exposed group:18F-dopa PET / CT imaging

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 95 Years

Inclusion criteria

Inclusion criteria: Patients attending the Medical Department of Neurology of Peking University Shenzhen Hospital from April 2024 to April 2029 were included in this study. The inclusion criteria are: 1 Subjects voluntarily participate in this trial and signed informed consent. 2. Age 45 and 95 (subject to the date of informed consent), gender is not limited. 3. PD patients who meet the PD diagnostic criteria in China. 4 Expected survival time of more than 12 months. 5. Willing and able to comply with diagnostic plans, clinical laboratory tests, and other trial procedures.

Exclusion criteria

Exclusion criteria: Subjects will be excluded from this study if any of the following conditions exist: 1.(1) The presence of neoplastic or significant cerebrovascular lesions; (2) neurosurgical or other neurological diseases, including epilepsy, encephalitis, or stroke; (3) clinically related mental illness; (4) current or recent history of drug or alcohol abuse / dependence. 2.There are thyroid dysfunction, vitamin B12 and folic acid deficiency, anemia, and neurosyphilis that may affect cognitive function. 3.Metabolic, immune, severe cardiac, liver, lung, renal disease, or tumors of any type were excluded. 4.Previous radionuclide administration and less than 10 physical half-lives apart from this study. 5.Is going or planning to participate in any drug or device clinical trial during the study. 6.Known allergy to the injection solution or its excipients. 7.Do not lie flat or remain still during the PET scan, or do not tolerate the PET scan. 8.Subjects with abnormalities in physical examination, ECG, EEG and clinical laboratory tests during the screening period that may affect safety or compliance.

Design outcomes

Primary

MeasureTime frame
MDS-Unified Parkinson's Disease Rating Scale score;Index mean striatal SUV to occipital SUV ratio;Laboratory indicators;

Secondary

MeasureTime frame
18F-DOPA PET / CT imaging visual analysis;Demographic characteristics;

Countries

China

Contacts

Public ContactMengjie Dong

PekingUniversityShenzhenHospital

dongmengjie@126.com+86 198 3286 1875

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026